X4 Pharmaceuticals (NASDAQ:XFOR) Upgraded at Zacks Research

Zacks Research upgraded shares of X4 Pharmaceuticals (NASDAQ:XFOR) to a strong-buy rating in a research note published on Tuesday morning,Zacks.com reports.

A number of other research analysts have also commented on XFOR. Stifel Nicolaus decreased their price objective on X4 Pharmaceuticals from $30.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday, August 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of X4 Pharmaceuticals in a report on Wednesday, October 8th. Finally, HC Wainwright set a $3.50 target price on shares of X4 Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $34.17.

X4 Pharmaceuticals Price Performance

XFOR opened at $3.09 on Tuesday. X4 Pharmaceuticals has a one year low of $1.35 and a one year high of $26.83. The company has a debt-to-equity ratio of 19.10, a current ratio of 3.19 and a quick ratio of 3.05. The company’s 50 day simple moving average is $3.34 and its 200-day simple moving average is $3.25. The stock has a market capitalization of $35.26 million, a P/E ratio of -0.21 and a beta of 0.54.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings results on Friday, August 8th. The company reported ($3.47) EPS for the quarter, beating the consensus estimate of ($4.53) by $1.06. The business had revenue of $1.97 million for the quarter, compared to analysts’ expectations of $1.62 million. X4 Pharmaceuticals had a negative net margin of 311.15% and a negative return on equity of 375.31%. Sell-side analysts anticipate that X4 Pharmaceuticals will post -0.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On X4 Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers boosted its stake in X4 Pharmaceuticals by 5.4% during the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after acquiring an additional 9,690 shares during the last quarter. Bank of America Corp DE boosted its stake in X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after acquiring an additional 22,485 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of X4 Pharmaceuticals by 9.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 481,528 shares of the company’s stock worth $114,000 after purchasing an additional 43,320 shares in the last quarter. Jane Street Group LLC boosted its position in shares of X4 Pharmaceuticals by 112.5% during the second quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock worth $185,000 after purchasing an additional 51,544 shares in the last quarter. Finally, Pale Fire Capital SE boosted its position in shares of X4 Pharmaceuticals by 45.2% during the first quarter. Pale Fire Capital SE now owns 2,035,362 shares of the company’s stock worth $481,000 after purchasing an additional 633,398 shares in the last quarter. Institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.